The Legal Examiner Mark The Legal Examiner Mark The Legal Examiner Mark search twitter facebook feed linkedin instagram google-plus avvo phone envelope checkmark mail-reply spinner error close
Skip to main content

Succumbing to pressure from industry regulators as well as mounting scientific data, Bayer AG has suspended sale of its antibleeding drug Traylol. The evidence has pointed to a greater than acceptable risk of death as a result of using the drug during heart transplant surgery. Safety issues for the drug began to surface in January 2006 when a report in the New England Journal of Medicine raised the specter of Trasylol’s higher risk of kidney failure, heart attacks, heart failure, and strokes. News has not improved since that time and it eventually led to the FDA telling Bayer to pull the drug from the market.

For more information on this subject, please refer to the section on Drugs, Medical Devices, and Implants.

Comments are closed.

Of Interest